Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 905 participants.
Also called NCT01516879
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 905 participants
- Sponsor
- Registry
-
NCT01516879
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Hungary, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT01516879. Randomized; quadruple masking; primary purpose treatment. Start 2012-01-05 (actual); primary completion 2013-10-14 (actual). Results posted on 2015-09-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
- Acronym
- DESCARTES
- Condition
- Hypercholesterolemia
- Intervention (Biological)
- Evolocumab
- Intervention (Biological)
- Placebo
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Ezetimibe
- Intervention (Other)
- Diet Only
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01516879- Content hash
de1d1db7b8fdd4725b41e05f1ff96d77f0288e078d57e2d99ee8c263d098d3d0